yourstate.us
21 CFR 886.4320

§ 886.4320 Corneal storage medium with preservatives including antifungals.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 886.4320, § 886.4320 Corneal storage medium with preservatives including antifungals, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/90985
Permanent ID
ys:prov:90985@1
SHA-256
8e84ae2c458198fa18ab5184cbf5989af135814f0fcc30e9ed655c7f6248c4eb

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Identification. Corneal storage medium with preservatives including antifungals is a device that is used to temporarily preserve human cornea tissue between harvesting and implantation. (b) Classification. Class II (special controls). The special controls for this device are: (1) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. (i) The following performance characteristics of the cornea following storage in the device must be demonstrated: (A) Endothelial cell density; (B) Endothelial cell morphology; (C) Corneal transparency; and (D) Central corneal thickness. (ii) Antimicrobial activity of the device must be demonstrated at the initial and maximum labeled storage time. (iii) Characterization of all preservatives, including antifungals, must include the following: (A) Characterization of impurities, heavy metal analysis, concentration, and dissolution; and (B) Chemical activity of all preservatives over the labeled use life of the device. (2) Performance data must demonstrate the sterility of the device. (3) The device must be demonstrated to be biocompatible and non-pyrogenic. (4) Performance data must support the claimed shelf life by demonstrating continued sterility, controlled bioburden, package integrity, and device functionality over the intended shelf life. (5) The device and each of its components (e.g., antifungal, antibiotic, medium) must be demonstrated to be compatible with their respective commercial container closure system/packaging. (6) An analysis must be provided that identifies and evaluates any contribution to the development and spread of antimicrobial resistance. (7) Labeling must include the following instructions: (i) Rinsing of cornea prior to transplantation; and (ii) Complete dissolution of all preservatives.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.